Tilray Brands (NASDAQ:TLRY) Trading Down 2.8% – Here’s What Happened

Tilray Brands, Inc. (NASDAQ:TLRY) dropped 2.8% during mid-day trading on Thursday . The stock traded as low as $4.41 and last traded at $4.46. 3,552,062 shares changed hands during trading, a decline of 17% from the average session volume of 4,289,494 shares. The stock had previously closed at $4.59.

Key Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Breckenridge Distillery won top honors at the San Francisco World Spirits Competition, with its Rum Cask Finish earning the highest award and Honey Whiskey taking gold. That kind of third-party validation can strengthen Tilray’s premium spirits positioning and brand credibility. Article Title
• Positive Sentiment: BrewDog, a Tilray-owned beer brand, announced the reopening of BrewDog Inverurie with a community-focused model designed to support local events and engagement. The relaunch adds another marketing and traffic catalyst for Tilray’s beverage business. Article Title
• Positive Sentiment: Montauk Brewing, another Tilray craft beer brand, kicked off summer with a 14th anniversary celebration, a limited-edition beer release, and a beach cleanup tied to its Surfrider Foundation partnership. The event highlights ongoing consumer engagement and brand-building activity. Article Title
• Positive Sentiment: BrewDog and Tilray Beer promoted a “world’s biggest bar tab” campaign tied to major tournament excitement, which could drive foot traffic and near-term beverage sales if participation is strong. Article Title
• Neutral Sentiment: A market-focused article noted TLRY among cannabis stocks “in focus,” but it did not report a specific operational catalyst. This is more a sentiment/watch-list item than a clear fundamental driver. Article Title

Analysts Set New Price Targets

Several research firms have weighed in on TLRY. Roth Mkm raised shares of Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Thursday, April 2nd. TD Cowen cut their price objective on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. ATB Cormark Capital Markets reduced their target price on Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a research note on Thursday, April 2nd. Weiss Ratings lowered Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Finally, Wall Street Zen raised Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.50.

Tilray Brands Trading Down 2.8%

The firm has a market cap of $519.81 million, a price-to-earnings ratio of -0.33 and a beta of 1.88. The firm’s 50-day moving average is $5.64 and its 200-day moving average is $7.28. The company has a current ratio of 2.79, a quick ratio of 1.66 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last released its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.10). Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.The business had revenue of $206.73 million for the quarter, compared to analyst estimates of $201.35 million. During the same quarter in the previous year, the company posted ($0.87) EPS. As a group, sell-side analysts anticipate that Tilray Brands, Inc. will post -0.58 EPS for the current fiscal year.

Insider Buying and Selling at Tilray Brands

In related news, Director David G. Hopkinson sold 33,556 shares of the company’s stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $6.94, for a total value of $232,878.64. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.84% of the stock is owned by corporate insiders.

Institutional Trading of Tilray Brands

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its holdings in shares of Tilray Brands by 1,839.7% in the first quarter. AQR Capital Management LLC now owns 607,054 shares of the company’s stock valued at $399,000 after purchasing an additional 575,757 shares in the last quarter. XTX Topco Ltd bought a new stake in Tilray Brands during the second quarter worth $112,000. Cerity Partners LLC grew its holdings in Tilray Brands by 98.5% during the second quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock worth $38,000 after buying an additional 45,929 shares in the last quarter. Ausdal Financial Partners Inc. bought a new stake in Tilray Brands during the second quarter worth $939,000. Finally, Bank of America Corp DE raised its position in Tilray Brands by 26.5% in the 2nd quarter. Bank of America Corp DE now owns 311,810 shares of the company’s stock valued at $129,000 after buying an additional 65,379 shares during the last quarter. 9.35% of the stock is owned by institutional investors.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.